LICENSE AGREEMENT BETWEEN LEXEO THERAPEUTICS, INC. AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA FORLicense Agreement • August 16th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This agreement (“Agreement”) is entered into by and between LEXEO Therapeutics, Inc., a Delaware corporation having an address at 430 East 29th Street, 14th Floor, New York, NY 10016 (“LICENSEE”) and The Regents of the University of California, a California public corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607- 5200 (“UNIVERSITY”), represented by its San Diego campus having an address at University of California, San Diego, Office of Innovation and Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (“UC San Diego”).
LICENSE AGREEMENTLicense Agreement • August 16th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This agreement (“Agreement”) is entered into by and between ARVC Therapeutics, Inc. a Delaware corporation having an address at 1396 Rubenstein Ave, Cardiff by the Sea, CA 92007 (“LICENSEE”) and The Regents of the University of California, a California public corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (“UNIVERSITY”), represented by its San Diego campus having an address at University of California, San Diego, Office of Innovation and Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (“UC San Diego”).
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • August 16th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Research Collaboration Agreement (this “Agreement”), effective as of February 3, 2021 (the “Effective Date”), is entered into by and between Cornell University, for and on behalf of its Joan & Sanford I. Weill Medical College, a New York education corporation with offices at 1300 York Avenue, New York, NY 10065 (“WCM”), and LEXEO Therapeutics, Inc., a Delaware corporation, having an office at 430 East 29th Street, 14th Floor, New York, NY 10016 (“Company”). WCM and Company each may be referred to herein as a “Party” and together as the “Parties.”
ContractFirst License Agreement • August 16th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances)
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
ContractLexeo Therapeutics, Inc. • August 16th, 2023 • Biological products, (no disgnostic substances)
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL..
LEXEO THERAPEUTICS, LLC CONSULTING AGREEMENTConsulting Agreement • August 16th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Consulting Agreement (the “Agreement”), made effective on this 9th day of October, 2020 (“Effective Date”) is entered into by LEXEO Therapeutics, LLC, a Delaware limited liability company (the “Company”), and Ronald G. Crystal, M.D. (the “Consultant”).
LICENSE AGREEMENTLicense Agreement • August 16th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This agreement (“Agreement”) is entered into as of the date of last signature below (the “Effective Date”) by and between STELIOS THERAPEUTICS, INC., a Delaware corporation having an address at 1396 Rubenstein Avenue, Cardiff by the Sea, California 92007 (“LICENSEE”) and The Regents of the University of California, a California public corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (“UNIVERSITY”), represented by its San Diego campus having an address at University of California, San Diego, Office of Innovation and Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (“UC SAN DIEGO”).
ContractFirst License Agreement • August 16th, 2023 • Lexeo Therapeutics, Inc. • Biological products, (no disgnostic substances)
[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
